ANSWER: B

Rationale:

The cardiac complication associated with ergot dopamine agonists — specifically pergolide and cabergoline — is a restrictive valvulopathy with regurgitation, caused by activation of 5-HT2B receptors on cardiac valve interstitial fibroblasts. This receptor activation promotes fibroblast proliferation, producing valvular changes indistinguishable from those caused by fenfluramine and methysergide. The non-ergot agonists — pramipexole, ropinirole, and rotigotine — are structurally distinct from ergot alkaloids and do not activate 5-HT2B receptors at therapeutic concentrations, which is why they do not carry this valvulopathy risk. Option B is correct.

• Option A: Option A is incorrect because D2 receptor affinity differences do not explain the valvulopathy risk; the ergot valvulopathy is a serotonin receptor effect, not a dopamine receptor effect.
• Option C: Option C is incorrect because, although the ergot valvulopathy is indeed cumulative and dose-dependent, the reason non-ergot agonists lack this risk is their absence of 5-HT2B receptor activity, not a difference in elimination kinetics; the option misattributes the protection to clearance rather than to receptor pharmacology.
• Option D: Option D is incorrect because non-ergot agonists act primarily at D2-family receptors (D2, D3, D4), not D1; none of the current agonists selectively stimulates D1 at therapeutic concentrations.
• Option E: Option E is incorrect because all dopamine agonists used in PD must cross the blood-brain barrier to produce their antiparkinsonian effect; peripheral receptor activity is separate from this and not the explanation for valvulopathy risk.

ANSWER: D

Rationale:

Pergolide and cabergoline cause cardiac valvulopathy through activation of 5-HT2B receptors expressed on interstitial fibroblasts of the cardiac valves. This receptor activation stimulates fibroblast proliferation and collagen deposition, producing a restrictive valvulopathy with regurgitation that is pathologically identical to the valve disease caused by fenfluramine and methysergide — two other drugs withdrawn for the same mechanism. Echocardiographic abnormalities were found in 20 to 30% of patients on long-term pergolide or cabergoline at doses used for PD, and the risk was cumulative with dose. Option D is correct.

• Option A: Option A is incorrect because D2 receptor activation in cardiac conduction tissue is not the mechanism of ergot valvulopathy; dopamine D2 receptors play no significant role in this complication.
• Option B: Option B is incorrect because pergolide is not a COMT inhibitor; COMT inhibitors are a separate drug class (entacapone, tolcapone) with a different mechanism and adverse effect profile.
• Option C: Option C is incorrect because alpha-adrenergic blockade causes vasodilation, not vasospasm, and is not the mechanism of ergot-related valvular disease.
• Option E: Option E is incorrect because pergolide is a direct dopamine receptor agonist, not a reuptake inhibitor; it does not cause norepinephrine release through a reuptake-blocking mechanism, and hypertensive valve damage is not the pathology observed.

ANSWER: A

Rationale:

The motor circuitry of the basal ganglia relies on coordinated activation of both D1 and D2 receptor pathways to produce full, balanced motor output. The direct pathway — which facilitates movement — is primarily driven by D1 receptor activation on striatonigral neurons. Levodopa-derived dopamine activates both D1 and D2 receptors in approximately physiological proportions. In contrast, all currently used non-ergot dopamine agonists (pramipexole, ropinirole, rotigotine) act primarily at D2-family receptors and do not meaningfully stimulate D1 receptors at therapeutic concentrations. This D1 deficit produces a ceiling effect on motor efficacy — the agonist can stimulate the indirect pathway (via D2) but cannot fully engage the direct pathway (via D1), resulting in incomplete motor benefit relative to levodopa. Option A is correct.

• Option B: Option B is incorrect because bioavailability is not the limiting factor; the ceiling on efficacy is pharmacodynamic, not pharmacokinetic.
• Option C: Option C is incorrect because dopamine agonists are not substrates for monoamine oxidase to the same extent as dopamine itself, and their half-lives are substantially longer than 2 hours (pramipexole and ropinirole: 6–12 hours).
• Option D: Option D is incorrect because the motor benefit of dopamine agonists is mediated through postsynaptic striatal D2 receptors, not presynaptic autoreceptors, and autoreceptor desensitization is not the mechanism limiting motor efficacy.
• Option E: Option E is incorrect because dopamine agonists do penetrate the blood-brain barrier effectively — this is a requirement for their antiparkinsonian action, and P-glycoprotein exclusion from the striatum is not a clinically significant factor for this drug class.

ANSWER: C

Rationale:

Pramipexole is eliminated almost entirely by renal excretion as unchanged drug, with less than 10% undergoing hepatic metabolism. This makes its clearance directly and proportionally dependent on renal function, so as creatinine clearance falls, pramipexole accumulates unless the dose is reduced. In renal impairment the adjustment is accomplished by lowering the starting dose, slowing titration, and capping the maximum daily dose according to the patient's CrCl, with greater restriction at lower levels of renal function. This is mandatory dose adjustment, not optional, and the prescriber should consult the current prescribing information for the specific CrCl thresholds and corresponding dose limits. Option C is correct.

• Option A: Option A is incorrect because ropinirole is cleared primarily by hepatic metabolism via CYP1A2, not by renal excretion; it does not require dose adjustment for renal impairment.
• Option B: Option B is incorrect because rotigotine undergoes hepatic metabolism and its transdermal route of delivery does not change the requirement for renal dose adjustment; no meaningful renal dose adjustment is required for rotigotine.
• Option D: Option D is incorrect because rotigotine's metabolites are not pharmacologically active in a clinically significant way that would require renal adjustment; this is not the basis for dose modification in renal disease.
• Option E: Option E is incorrect because CYP1A2 activity is a hepatic enzyme function and is not regulated by or proportional to glomerular filtration rate; the premise of this option conflates renal and hepatic clearance mechanisms.

ANSWER: E

Rationale:

Ropinirole is metabolized primarily by CYP1A2 in the liver. Fluvoxamine is one of the most potent clinically available inhibitors of CYP1A2 and can increase ropinirole plasma concentrations by up to 80% when added to a stable ropinirole regimen. This pharmacokinetic interaction reduces ropinirole clearance, causing drug accumulation and the emergence of dose-related adverse effects including nausea, dizziness, and excessive sedation — all classic signs of ropinirole toxicity. The clinical management requires ropinirole dose reduction when fluvoxamine is co-administered. Option E is correct.

• Option A: Option A is incorrect because fluvoxamine is a selective serotonin reuptake inhibitor (SSRI), not a dopamine receptor antagonist; it does not block D2 receptors and does not antagonize ropinirole's mechanism of action.
• Option B: Option B is incorrect because ropinirole is cleared by hepatic metabolism via CYP1A2, not by renal tubular secretion; fluvoxamine does not affect renal tubular transport.
• Option C: Option C is incorrect because fluvoxamine inhibits, not activates, monoamine oxidase — and ropinirole is not primarily metabolized by MAO; furthermore, MAO-B inhibition would increase, not decrease, dopaminergic tone.
• Option D: Option D is incorrect because plasma protein binding displacement is rarely the primary mechanism of clinically significant drug interactions; ropinirole's interaction with fluvoxamine is a metabolic enzyme inhibition effect, not a protein binding displacement effect.

ANSWER: B

Rationale:

Rotigotine is the only dopamine agonist available as a transdermal patch, delivering drug continuously through the skin at a constant rate over 24 hours. This transdermal route completely bypasses the need for oral ingestion and gastrointestinal absorption, making it uniquely suited to perioperative management when patients must remain NPO. The patch can be applied the evening before surgery and maintained throughout and after the procedure without interruption. This is an established and guideline-supported use of rotigotine. Option B is correct.

• Option A: Option A is incorrect because while pramipexole could theoretically be delivered via nasogastric tube, this requires placement of a nasogastric tube, which is invasive and not routinely employed for this purpose; rotigotine's non-invasive transdermal route is clearly preferable.
• Option C: Option C is incorrect because ropinirole extended-release is an oral formulation designed for gastrointestinal absorption; there is no established or approved rectal formulation, and rectal administration of oral tablets is not a standard practice.
• Option D: Option D is incorrect because while subcutaneous apomorphine infusion is used in advanced PD for motor complications, it is not initiated perioperatively in patients without an established infusion regimen; it requires a pre-titration period, antiemetic pretreatment, and patient training — none of which would be appropriate to start 24 hours before surgery.
• Option E: Option E is incorrect because cabergoline is an ergot agonist associated with fibrotic valvulopathy and is not recommended for initiation in PD; its use would not be appropriate regardless of its convenient dosing interval.

ANSWER: D

Rationale:

Despite its name, apomorphine is not an opioid and has no affinity for opioid receptors. The name reflects its chemical origin — apomorphine was originally synthesized from morphine through a dehydration reaction — but the resulting compound has a pharmacological profile that is entirely different from opioids. Apomorphine is a potent, broad-spectrum dopamine receptor agonist, acting at D1, D2, D3, and D4 receptors. It produces its antiparkinsonian effect through dopamine receptor activation in the striatum, not through any opioid mechanism. Patients and caregivers can be clearly reassured that concerns about opioid side effects — including respiratory depression, dependence, and constipation — do not apply to apomorphine. Option D is correct.

• Option A: Option A is incorrect because apomorphine has no opioid receptor activity whatsoever and does not produce respiratory depression through an opioid mechanism.
• Option B: Option B is incorrect because apomorphine does not share opioid receptor activity; the structural relationship to morphine is a chemical synthesis fact, not a pharmacological one.
• Option C: Option C is incorrect because apomorphine is not an opioid antagonist; it was not developed to reverse morphine overdose, and it has no blocking activity at opioid receptors.
• Option E: Option E is incorrect because apomorphine's mechanism in Parkinson's disease is direct dopamine receptor agonism, not opioid receptor modulation of dopamine release; while opioid receptors exist in the basal ganglia, they are not the target of apomorphine therapy.

ANSWER: A

Rationale:

Apomorphine is distinguished from pramipexole, ropinirole, and rotigotine by its broad receptor profile: it is a potent full agonist at D1, D2, D3, and D4 receptors. The non-ergot oral agonists act primarily at D2-family receptors and do not reliably stimulate D1 receptors at therapeutic concentrations. Because D1 receptor activation on striatonigral neurons is required for full expression of the direct-pathway motor benefit, apomorphine's D1 agonism produces a qualitatively more complete motor response — one that more closely resembles the effect of levodopa-derived dopamine, which also activates both D1 and D2 receptors in approximately physiological proportions. This is why the motor response to subcutaneous apomorphine is comparable to that of a levodopa rescue dose at peak effect. Option A is correct.

• Option B: Option B is incorrect because the shorter half-life of apomorphine (approximately 40 minutes) produces a brief, pulsatile effect that is useful for rescue — but pulsatility is not the reason its motor response resembles levodopa; the explanation is receptor profile breadth, specifically D1 activity.
• Option C: Option C is incorrect because apomorphine is not a prodrug for levodopa; it acts directly as a dopamine receptor agonist and is not converted to levodopa in any tissue.
• Option D: Option D is incorrect because apomorphine's motor benefit in PD does not depend on surviving nigrostriatal terminals; it acts directly at postsynaptic striatal receptors, which is why it remains effective even in advanced disease when terminal density is severely depleted.
• Option E: Option E is incorrect because while CNS penetration is necessary for any antiparkinsonian agent, the completeness of motor response is determined by the receptor profile engaged at the striatum, not by the rate of blood-brain barrier penetration.

ANSWER: C

Rationale:

The pharmacokinetic profile of subcutaneous apomorphine is among the most favorable of any antiparkinsonian agent for acute rescue use. After subcutaneous injection, apomorphine is rapidly absorbed, with peak plasma concentrations reached within 10 to 20 minutes. The onset of motor benefit occurs within 4 to 12 minutes of injection — faster than any oral antiparkinsonian agent — and the duration of action is 45 to 90 minutes per dose. The plasma half-life is approximately 40 minutes, consistent with this brief but therapeutically adequate duration. This rapid onset and short duration make subcutaneous apomorphine ideally suited to managing discrete off episodes: the drug works quickly enough to rescue the patient from an off state, and its effect subsides within the window of a typical off episode without accumulating. Option C is correct.

• Option A: Option A is incorrect because apomorphine's half-life is approximately 40 minutes, not 6 hours, and it reaches peak concentrations within 10 to 20 minutes, not 60 minutes; it is used for acute rescue, not once-daily prophylaxis.
• Option B: Option B is incorrect because apomorphine is administered subcutaneously, not transdermally; there is no transdermal apomorphine formulation approved for PD.
• Option D: Option D is incorrect because apomorphine's half-life is approximately 40 minutes; a 4-hour half-life is incorrect and would not allow a single morning dose to prevent off episodes throughout the day.
• Option E: Option E is incorrect because subcutaneous apomorphine absorption is rapid, not slow; a 4-to-6-hour absorption profile would eliminate the rapid onset that is the primary clinical advantage of this route of administration.

ANSWER: E

Rationale:

Ondansetron and other 5-HT3 antagonists (granisetron, dolasetron) are contraindicated with apomorphine. The combination of subcutaneous apomorphine with a 5-HT3 antagonist has been associated with severe, sometimes profound hypotension and loss of consciousness, as well as QTc prolongation that predisposes to cardiac arrhythmias including torsades de pointes. Because of these reports, 5-HT3 antagonists are contraindicated as a class for antiemetic use during apomorphine therapy. Domperidone — a peripherally acting D2 antagonist that does not cross the blood-brain barrier — is the antiemetic of choice for apomorphine initiation, started 3 days before the first dose and continued through the titration period. Option E is correct.

• Option A: Option A is incorrect because ondansetron's mechanism is 5-HT3 antagonism, not dopamine D2 antagonism; it does not block D2 receptors and would not directly antagonize apomorphine's antiparkinsonian effect through dopamine receptor blockade.
• Option B: Option B is incorrect because ondansetron is not a CYP3A4 inducer; it is metabolized by CYP3A4 and CYP1A2 but does not induce these enzymes to a clinically significant degree.
• Option C: Option C is incorrect because ondansetron does not cause irreversible binding to serotonin receptors; its 5-HT3 antagonism is competitive and reversible, and this is not the mechanism of its contraindication with apomorphine.
• Option D: Option D is incorrect because ondansetron is a 5-HT3 antagonist — it blocks, not activates, 5-HT3 receptors; its antiemetic effect comes from 5-HT3 blockade in the chemoreceptor trigger zone, not 5-HT3 activation.

ANSWER: B

Rationale:

Domperidone is the antiemetic of choice when initiating apomorphine therapy. It is a peripherally acting D2 antagonist that blocks dopamine receptors in the gut and in the chemoreceptor trigger zone — which lies outside the blood-brain barrier — without penetrating the central nervous system to any significant degree. This peripheral selectivity means domperidone provides effective antiemetic coverage without blocking the central D2 receptors that apomorphine must activate for its antiparkinsonian effect, and without the QTc-prolonging interaction that contraindicates ondansetron and other 5-HT3 antagonists in this context. Standard practice is to start domperidone 20 mg three times daily for 3 days before the first apomorphine dose and continue through titration. Option B is correct.

• Option A: Option A is incorrect because metoclopramide crosses the blood-brain barrier and blocks central D2 receptors; it is contraindicated in Parkinson's disease because it worsens motor function and can precipitate acute motor deterioration.
• Option C: Option C is incorrect because prochlorperazine is a phenothiazine antipsychotic with potent central D2 antagonism; it is contraindicated in PD for the same reason as metoclopramide — central D2 blockade worsens parkinsonism.
• Option D: Option D is incorrect because ondansetron and other 5-HT3 antagonists are specifically contraindicated with apomorphine due to combined QTc prolongation risk and the potential for severe hypotension and arrhythmias.
• Option E: Option E is incorrect because haloperidol is a high-potency D2 antagonist with significant central receptor blockade even at low doses; it worsens Parkinson's motor symptoms and is contraindicated in PD, and there is no dose that is both an effective antiemetic and devoid of central D2 blockade in this patient population.

ANSWER: D

Rationale:

The pivotal randomized trial comparing ropinirole versus levodopa as initial therapy (the 056 Study Group trial) demonstrated that patients assigned to initial ropinirole therapy had a dyskinesia incidence of approximately 20% at 5 years, compared with approximately 45% in the initial levodopa group. This approximately 25 percentage point reduction in dyskinesia risk at 5 years provided the primary evidence base for the agonist-first strategy in younger PD patients. However, these results require qualification: the majority of ropinirole-treated patients required supplemental levodopa within 2 to 3 years, and the lower dyskinesia rate in the agonist group reflected at least in part a lower cumulative levodopa exposure rather than a lasting protective effect of agonists alone. The trial established that agonist-first delays but does not eliminate dyskinesia. Option D is correct.

• Option A: Option A is incorrect because the trial did demonstrate a meaningful difference in dyskinesia rates; ropinirole-treated patients had substantially lower dyskinesia incidence than levodopa-treated patients at 5 years.
• Option B: Option B is incorrect because dopamine agonists produce lower dyskinesia rates than levodopa, not higher; the mechanism relates to more continuous receptor stimulation and lower intrinsic sensitization potential.
• Option C: Option C is incorrect because dyskinesia rates were not below 5% in either group at 5 years; the 45% rate in the levodopa group reflects the well-established cumulative dyskinesia burden of long-term levodopa therapy.
• Option E: Option E is incorrect because levodopa does not produce less dyskinesia than ropinirole; the opposite is true — levodopa's pulsatile receptor stimulation (particularly with immediate-release formulations) is associated with higher dyskinesia risk than the more continuous stimulation produced by longer-acting agonists.

ANSWER: A

Rationale:

A critical and frequently misunderstood finding from both the ropinirole versus levodopa (056 Study Group) and pramipexole versus levodopa (Parkinson Study Group) trials is that most patients assigned to initial agonist monotherapy required supplemental levodopa within 2 to 3 years of follow-up. Disease progression in Parkinson's disease continues regardless of the initial drug chosen, and dopamine agonists alone eventually become insufficient to maintain adequate motor control as nigrostriatal degeneration advances. The agonist-first strategy delays dyskinesia development — in part because total cumulative levodopa exposure is lower when supplementation is delayed — but it does not eliminate the eventual need for levodopa. Clinicians should counsel patients that agonist-first is not a levodopa-avoidance strategy, but a dyskinesia-delay strategy that has real but qualified benefits. Option A is correct.

• Option B: Option B is incorrect because the proportion of patients sustaining adequate motor control on agonist monotherapy through 5 years was substantially lower than 80%; the majority of agonist-treated patients did require levodopa supplementation by 2 to 3 years.
• Option C: Option C is incorrect because the decision to add levodopa is driven by insufficient motor control with agonist monotherapy, not by the emergence of dyskinesias; levodopa supplementation is not used to smooth dyskinesias caused by agonists.
• Option D: Option D is incorrect because the trials were not terminated at 2 years; both ran for 4 to 5 years, and disease progression was not found to be faster in agonist-treated patients than levodopa-treated patients — neither agent has proven neuroprotective effects.
• Option E: Option E is incorrect because the trials did not identify age 50 as a threshold for sustained agonist monotherapy; the age guidance for agonist-first strategy (approximately under 60 years) relates to the risk-benefit balance of adverse effects relative to dyskinesia prevention, not to the ability to avoid levodopa indefinitely.

ANSWER: C

Rationale:

The decision to initiate a dopamine agonist rather than levodopa in early Parkinson's disease is guided primarily by the patient's age and cognitive status. In patients under approximately 60 years at diagnosis with preserved cognition, agonist-first is a reasonable strategy: the dyskinesia-delay benefit is most clinically meaningful when the patient has a long expected disease course, because delaying dyskinesia onset by 2 to 5 years is more valuable when the patient will live with PD for decades. In patients over approximately 70 years — and particularly those with pre-existing cognitive impairment — the risk-benefit calculation reverses: the adverse effects of dopamine agonists (cognitive worsening, excessive somnolence, impulse control disorders) are substantially more common and severe in older patients and those with cognitive vulnerability, while the dyskinesia-prevention benefit is less clinically meaningful given the shorter expected disease duration. Levodopa remains the most effective antiparkinsonian agent and is the preferred initial therapy for older patients. Option C is correct.

• Option A: Option A is incorrect because agonist-first is not recommended across all age groups; the cognitive, somnolence, and impulse control risks of agonists outweigh the dyskinesia benefit in older patients, particularly those with cognitive impairment.
• Option B: Option B is incorrect because levodopa is not always the initial choice; in younger patients with preserved cognition, agonist-first is guideline-supported and reduces early dyskinesia risk.
• Option D: Option D is incorrect because switching to a dopamine agonist after levodopa-induced dyskinesias have developed does not reduce the dyskinesia burden that has already emerged; the agonist-first strategy must be applied from the outset to have its dyskinesia-delay effect.
• Option E: Option E is incorrect because older patients do not tolerate dopamine agonists better than younger patients; the opposite is true — older age is associated with greater sensitivity to agonist adverse effects including confusion, hallucinations, somnolence, and falls.

ANSWER: E

Rationale:

Impulse control disorders (ICDs) are the most clinically significant class-specific adverse effect of dopamine agonists. They reflect D3 receptor-mediated overactivation of the mesolimbic reward pathway — particularly the nucleus accumbens and its connections to the prefrontal cortex. Pramipexole and ropinirole both have greater relative affinity for D3 receptors than for D2 receptors, and D3 receptors are expressed at particularly high density in limbic structures involved in reward processing. Overactivation of this circuit sensitizes reward-seeking behavior, producing a spectrum of compulsive behaviors including pathological gambling, hypersexuality, compulsive eating, and compulsive shopping. ICDs occur in 10 to 20% of patients on therapeutic agonist doses, and many patients do not spontaneously report them due to shame or lack of awareness that the behaviors are medication-related. Clinicians must screen specifically at every visit. Option E is correct.

• Option A: Option A is incorrect because pramipexole does not inhibit serotonin reuptake; it is a dopamine receptor agonist with no meaningful serotonin transporter activity, and the mechanism of ICDs is D3-mediated, not serotonergic.
• Option B: Option B is incorrect because D1 receptors in the motor cortex are not the mechanism of impulse control disorders; pramipexole has minimal D1 activity, and cortical GABAergic disinhibition is not the pathophysiology of ICDs.
• Option C: Option C is incorrect because pramipexole does not non-specifically activate all neurotransmitter receptors; its pharmacological actions are selective to D2-family dopamine receptors, and ICD development is a receptor-specific effect, not a consequence of drug accumulation.
• Option D: Option D is incorrect because the ICD mechanism is postsynaptic D3 receptor overactivation in the limbic system, not presynaptic autoreceptor activation triggering endogenous dopamine release; in advanced PD, the density of surviving dopaminergic terminals in the nucleus accumbens is reduced, limiting the relevance of autoreceptor mechanisms.

ANSWER: B

Rationale:

Impulse control disorders occur in 10 to 20% of patients on therapeutic doses of dopamine agonists — a rate substantially higher than the background prevalence of these behaviors in the general population and in PD patients not on agonist therapy. The primary management strategy is agonist dose reduction or, if the ICD is severe or the patient cannot tolerate any agonist dose that does not cause ICDs, agonist discontinuation. ICDs are driven by D3-receptor-mediated overactivation of the mesolimbic reward pathway, and reducing agonist exposure decreases D3 stimulation in the nucleus accumbens, typically leading to resolution or substantial improvement of the compulsive behaviors. In patients who cannot tolerate agonist withdrawal because of unacceptable motor deterioration, options include clozapine or deep brain stimulation to allow agonist dose reduction, but these are second-line considerations. Option B is correct.

• Option A: Option A is incorrect because ICDs are substantially more common than 1%; rates of 10 to 20% have been reported in multiple large cross-sectional studies, and the management is agonist dose modification, not antipsychotic addition.
• Option C: Option C is incorrect because the prevalence is not 50 to 60%; rates of 10 to 20% are well established. Additionally, pramipexole has higher D3 affinity than ropinirole, not lower — switching to pramipexole would not reduce D3-mediated ICD risk.
• Option D: Option D is incorrect because ICDs do not resolve spontaneously in most patients while the agonist dose remains unchanged; the trigger (D3 receptor overactivation by the agonist) persists as long as the agonist is continued at the same dose, and watchful waiting without dose modification is not the recommended approach.
• Option E: Option E is incorrect because the prevalence is not fewer than 5%, and adding levodopa to allow agonist dose reduction is a reasonable approach in some patients, but this is not the primary standard recommendation; dose reduction or discontinuation of the agonist itself is the first intervention.

ANSWER: D

Rationale:

Excessive daytime sleepiness (EDS) and sudden sleep attacks are a well-established and potentially dangerous adverse effect of dopamine agonists. Sleep attacks — episodes of sudden, irresistible sleep onset without preceding warning — have been reported during driving and other activities requiring sustained attention, with serious consequences in published case series. All patients initiating dopamine agonist therapy must receive explicit counseling about this risk before leaving the clinic. They should be instructed to assess their level of alertness and their fitness to drive, to avoid driving or operating machinery if they experience any abnormal daytime sleepiness, and to contact their prescriber promptly if episodes of excessive sleepiness or sudden sleep onset occur. This counseling is mandatory for all dopamine agonists as a class and is a patient safety obligation, not an optional disclosure. Option D is correct.

• Option A: Option A is incorrect because ropinirole does not inhibit monoamine oxidase; it is a dopamine receptor agonist. The tyramine interaction and dietary restriction apply to MAO inhibitors such as selegiline and rasagiline, which are a separate class of antiparkinsonian agents.
• Option B: Option B is incorrect because ropinirole does not cause hyperglycemia through D2 receptor blockade in pancreatic beta cells; it is a dopamine receptor agonist, not an antagonist, and blood glucose monitoring is not indicated.
• Option C: Option C is incorrect because antacids do not have a clinically significant interaction with ropinirole; food may delay the time to peak concentration but does not reduce bioavailability by a clinically meaningful amount, and no antacid restriction applies.
• Option E: Option E is incorrect because food does not increase ropinirole's first-pass metabolism; while food delays Tmax, it does not reduce overall bioavailability by 40%, and ropinirole can be taken with or without food.

ANSWER: A

Rationale:

Dopamine dysregulation syndrome (DDS) is a compulsive overuse of dopaminergic medications — most commonly levodopa but also dopamine agonists — in which patients take the drugs in excess of the doses required for motor control. The behavior is driven by the hedonic and stimulant-like effects produced by high-dose dopaminergic activity in the mesolimbic system, and patients resist dose reduction even when the excess causes severe dyskinesias and psychiatric complications. DDS shares pathophysiological features with substance addiction and is associated with young-onset PD, male sex, prior history of substance misuse, and impulsive personality traits. It is distinct from impulse control disorders in that the compulsive behavior in DDS targets the medications themselves — the patient is addicted to the dopaminergic drugs — whereas ICDs involve external reward activities (gambling, hypersexuality, shopping) that are driven by D3-mediated reward pathway sensitization. DDS and ICD frequently co-exist. Option A is correct.

• Option B: Option B is incorrect because while DDS and ICDs share some pathophysiological overlap, medication-seeking compulsive overuse is specifically classified as DDS, not as an ICD; they are conceptually and clinically distinct entities requiring different management approaches.
• Option C: Option C is incorrect because DDS is not called "dopaminergic withdrawal syndrome"; the patient is not experiencing withdrawal from normal doses — he is taking excess doses compulsively; the framing in option C misidentifies both the syndrome name and the mechanism.
• Option D: Option D is incorrect because this is not a case of underprescribing or appropriate dose self-titration; the patient is taking doses that are producing severe dyskinesias and worsening his overall motor state, and increasing the prescribed dose would exacerbate the problem.
• Option E: Option E is incorrect because tachyphylaxis involving D2 receptor downregulation is not the mechanism of this presentation; while some receptor adaptation occurs with chronic levodopa therapy, the clinical picture of compulsive overuse against medical advice, driven by hedonic effects, is DDS, not pharmacodynamic tolerance.

ANSWER: C

Rationale:

Hallucinations in agonist-treated Parkinson's disease patients are most commonly drug-induced, reflecting dopaminergic overstimulation of mesolimbic receptors, and are more common in older patients, those with cognitive impairment, and those on higher agonist doses. When hallucinations emerge in an agonist-treated patient, the first management step is agonist dose reduction or discontinuation — not the addition of an antipsychotic. This is because the hallucinations are drug-induced and often resolve or substantially improve with dose reduction alone, without requiring any antipsychotic therapy. Adding an antipsychotic without first reducing the causative agent leaves the trigger in place and unnecessarily exposes the patient to additional medication risks. If dose reduction is insufficient or not feasible, then — and only then — should an antipsychotic be considered, and the choice must be restricted to quetiapine or clozapine (see Q20). Option C is correct.

• Option A: Option A is incorrect because adding quetiapine without first attempting dose reduction of the causative agent is not the first-line approach; dose reduction should precede antipsychotic addition.
• Option B: Option B is incorrect because haloperidol is specifically contraindicated in Parkinson's disease; it is a high-potency D2 antagonist that blocks central dopamine receptors and causes severe worsening of parkinsonism and potentially irreversible motor deterioration.
• Option D: Option D is incorrect because abrupt discontinuation of all antiparkinsonian medications is dangerous; it carries the risk of neuroleptic malignant syndrome-like parkinsonism-hyperpyrexia syndrome and should never be done abruptly. Dose reduction of the agonist, not complete discontinuation of all therapy, is the first step.
• Option E: Option E is incorrect because visual hallucinations in the context of dopamine agonist therapy are a recognized and common adverse effect that does not require neuroimaging before medication adjustment; brain MRI would be indicated if there were clinical features suggesting a structural cause (new focal neurological signs, headache, atypical presentation) that are not present here.

ANSWER: E

Rationale:

When antipsychotic therapy is required in Parkinson's disease — typically for refractory hallucinations or psychosis that does not resolve with dopaminergic dose reduction — quetiapine and clozapine are the antipsychotics used, because their very low striatal D2 receptor occupancy minimizes motor worsening. Most other antipsychotics, including first-generation agents (haloperidol, chlorpromazine) and most other second-generation (atypical) agents (risperidone, olanzapine, aripiprazole, ziprasidone), block striatal D2 receptors sufficiently to worsen motor function in PD patients, often dramatically. Quetiapine has very low affinity for D2 receptors relative to its affinity for other receptors (particularly histamine H1 and serotonin 5-HT2A), resulting in minimal striatal D2 occupancy at clinical doses. Clozapine has the lowest D2 receptor affinity of any antipsychotic, producing effective antipsychotic activity through non-D2 mechanisms while sparing motor function; it requires REMS (Risk Evaluation and Mitigation Strategy) monitoring for agranulocytosis. Pimavanserin — a selective 5-HT2A inverse agonist with no D2 activity — is a mechanistically distinct option approved specifically for PD psychosis. Option E is correct because it identifies the agents that can be used and explains why the others must be avoided, without overstating the restriction as an absolute limit of two drugs.

• Option A: Option A is incorrect because risperidone and olanzapine have clinically significant striatal D2 blockade and both worsen parkinsonism; they are specifically contraindicated in PD and are not the preferred agents despite being atypical antipsychotics.
• Option B: Option B is incorrect because the characterization that atypical antipsychotics as a class have no significant D2 blockade is false; while they have lower D2 affinity than typical agents, most atypical antipsychotics still produce sufficient striatal D2 blockade to worsen PD motor symptoms at clinical doses.
• Option C: Option C is incorrect because first-generation antipsychotics have the highest D2 receptor affinity and cause the most severe worsening of parkinsonism; haloperidol is among the most contraindicated drugs in PD.
• Option D: Option D is incorrect because quetiapine and clozapine can be used safely in PD; declaring that no antipsychotic is safe overstates the restriction and leaves patients without necessary treatment options when hallucinations cannot be managed by dose reduction alone.

ANSWER: B

Rationale:

The distinction between pramipexole and ropinirole in the setting of renal impairment is one of the most clinically important pharmacokinetic differences between these two agents. Pramipexole is eliminated almost entirely by renal excretion as unchanged drug, with less than 10% undergoing hepatic metabolism. Its clearance is therefore directly proportional to creatinine clearance, and dose reduction is mandatory in renal impairment — accomplished by lowering the starting dose, slowing titration, and capping the maximum daily dose, with progressively greater restriction as CrCl falls. For a patient with advanced (stage 4) chronic kidney disease such as Patient A, this means a substantially reduced regimen relative to a patient with normal renal function. Ropinirole, by contrast, is cleared primarily by hepatic metabolism via CYP1A2, with renal excretion playing a minor role. It does not require dose adjustment for renal impairment and can be used at standard doses even in advanced CKD, provided hepatic function is adequate. Option B is correct.

• Option A: Option A is incorrect because only pramipexole requires renal dose adjustment; ropinirole's primary elimination is hepatic and renal dose adjustment is not required.
• Option C: Option C is incorrect because pramipexole does not undergo extensive hepatic first-pass metabolism — its oral bioavailability is approximately 90% precisely because it is minimally metabolized hepatically; it reaches the systemic circulation largely intact and is then eliminated renally.
• Option D: Option D is incorrect because CYP1A2 activity is not regulated by or proportional to glomerular filtration rate; hepatic CYP enzyme activity and renal function are independent, and ropinirole's clearance does not decline in proportion to GFR.
• Option E: Option E is incorrect because ropinirole does not require dose reduction in renal impairment, and characterizing ropinirole renal dose adjustment as "optional" is misleading; the evidence-based guidance is that renal dose adjustment for ropinirole is not required.

ANSWER: D

Rationale:

Cigarette smoke contains polycyclic aromatic hydrocarbons that are potent inducers of CYP1A2 — the hepatic enzyme responsible for the primary metabolic clearance of ropinirole. During active smoking, CYP1A2 induction increases the rate of ropinirole metabolism, keeping plasma concentrations lower than they would be in a non-smoker at the same dose. When the patient quits smoking, the CYP1A2 induction gradually reverses over 1 to 4 weeks, returning enzyme activity toward baseline. At the same ropinirole dose, metabolism slows, plasma concentrations rise — by an amount that can be clinically significant — and signs of ropinirole toxicity (nausea, dizziness, somnolence) emerge even though the dose has not changed. The clinical management is to reduce the ropinirole dose when a patient on ropinirole quits smoking, anticipating this pharmacokinetic change. This is the exact mirror image of the fluvoxamine interaction: both situations produce rising ropinirole concentrations through CYP1A2 inhibition or de-induction, requiring dose reduction. Option D is correct.

• Option A: Option A is incorrect because nicotine withdrawal does not directly activate D3 receptors in a way that pharmacodynamically amplifies ropinirole toxicity; the interaction is pharmacokinetic — a change in drug metabolism — not pharmacodynamic.
• Option B: Option B is incorrect because smoking cessation does not meaningfully reduce gastric acid secretion, and ropinirole's bioavailability is not significantly dependent on gastric pH; this is not the mechanism of rising plasma concentrations after smoking cessation.
• Option C: Option C is incorrect because ropinirole is not eliminated by renal tubular secretion — it is hepatically cleared via CYP1A2; nicotine has no inhibitory effect on renal tubular secretion of ropinirole, and the plasma concentrations after smoking cessation rise, not fall.
• Option E: Option E is incorrect because smoking cessation does not activate hepatic P-glycoprotein, and P-glycoprotein is not the primary elimination mechanism for ropinirole; this option incorrectly identifies both the transporter and the direction of the pharmacokinetic effect.